Department of Gynecology Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
Department of Obstetrics and Gynecology, Yancheng No. 1 People's Hospital, Yancheng 224000, China.
Ann Palliat Med. 2020 May;9(3):912-920. doi: 10.21037/apm.2020.04.01. Epub 2020 Apr 28.
This study aims to evaluate the role systematic lymphadenectomy (SL) p l a y s in advanced ovarian cancer (OC) patients. A meta-analysis was done to compare the progression-free survival (PFS) rates and overall survival (OS) rates between SL and unsystematic lymphadenectomy (USL).
An extensive literature search from the dates of January 1, 1994, to today was performed. In total, we analyzed 15 studies [3 randomized controlled trials (RCTs) and 12 observation studies], which included 33,257 patients with advanced OC who underwent SL or USL. We compared the survival outcomes of PFS and OS between SL and USL stratified by research type, respectively. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were combined and analyzed by using the Revman 5.3 software.
For RCTs, SL did not improve the survival outcomes for advanced OC. Only 2 RCTs compared PFS, and 3 RCTs compared the OS rates between SL and USL. Two RCTs demonstrated that there was no difference in PFS between SL and USL (HR: 0.91; 95% CI: 0.81-1.04; P=0.16>0.05); at the same time, 3 RCTs also demonstrated that there were no difference in OS between SL and USL (HR: 0.94, 95% CI: 0.88-1.00; P=0.07>0.05). However, in observational studies, SL showed increased PFS (HR: 0.93, 95% CI: 0.92-0.95; P<0.00001) and OS (HR: 0.91, 95% CI: 0.89-0.93, P<0.00001) for advanced OC patients. The heterogeneity and publication bias in the included studies were within acceptable thresholds.
These findings suggest the possibility that SL cannot improve survival outcomes for advanced OC patients. However, we cann ot completely ignore the results of observational studies. More relevant RCTs are needed to investigate the role of SL for advanced OC patients.
本研究旨在评估系统性淋巴结清扫术(SL)在晚期卵巢癌(OC)患者中的作用。进行了一项荟萃分析,以比较 SL 和非系统性淋巴结清扫术(USL)的无进展生存期(PFS)率和总生存期(OS)率。
从 1994 年 1 月 1 日到今天,进行了广泛的文献检索。总共分析了 15 项研究[3 项随机对照试验(RCT)和 12 项观察性研究],其中包括 33257 名接受 SL 或 USL 的晚期 OC 患者。我们分别按研究类型比较了 SL 和 USL 之间 PFS 和 OS 的生存结局。使用 Revman 5.3 软件合并并分析了合并风险比(HRs)和 95%置信区间(CIs)。
对于 RCT,SL 并未改善晚期 OC 的生存结局。只有 2 项 RCT 比较了 PFS,3 项 RCT 比较了 SL 和 USL 之间的 OS 率。2 项 RCT 表明 SL 和 USL 之间的 PFS 无差异(HR:0.91;95%CI:0.81-1.04;P=0.16>0.05);同时,3 项 RCT 也表明 SL 和 USL 之间的 OS 无差异(HR:0.94,95%CI:0.88-1.00;P=0.07>0.05)。然而,在观察性研究中,SL 显示出晚期 OC 患者的 PFS(HR:0.93,95%CI:0.92-0.95;P<0.00001)和 OS(HR:0.91,95%CI:0.89-0.93,P<0.00001)的增加。纳入研究的异质性和发表偏倚均在可接受的范围内。
这些发现表明,SL 可能无法改善晚期 OC 患者的生存结局。然而,我们不能完全忽略观察性研究的结果。需要更多相关的 RCT 来研究 SL 对晚期 OC 患者的作用。